OpenSAFELY: Do adults prescribed non-steroidal anti-inflammatory drugs have an increased risk of death from COVID-19?

Author:

,Wong Angel YSORCID,MacKenna BrianORCID,Morton Caroline EORCID,Schultze AnnaORCID,Walker Alex JORCID,Bhaskaran KrishnanORCID,Brown Jeremy PORCID,Rentsch Christopher TORCID,Williamson ElizabethORCID,Drysdale Henry,Croker RichardORCID,Bacon SebORCID,Hulme William,Bates ChrisORCID,Curtis Helen JORCID,Mehrkar Amir,Evans David,Inglesby Peter,Cockburn Jonathan,McDonald Helen IORCID,Tomlinson LaurieORCID,Mathur RohiniORCID,Wing KevinORCID,Forbes HarrietORCID,Parry John,Hester Frank,Harper Sam,Evans Stephen JWORCID,Smeeth LiamORCID,Douglas Ian JORCID,Goldacre BenORCID

Abstract

AbstractImportanceThere has been speculation that non-steroidal anti-inflammatory drugs (NSAIDs) may negatively affect coronavirus disease 2019 (COVID-19) outcomes, yet clinical evidence is limited.ObjectiveTo assess the association between NSAID use and deaths from COVID-19 using OpenSAFELY, a secure analytical platform.DesignTwo cohort studies (1st March-14th June 2020).SettingWorking on behalf of NHS England, we used routine clinical data from >17 million patients in England linked to death data from the Office for National Statistics.ParticipantsStudy 1: General population (people with an NSAID prescription in the last three years). Study 2: people with rheumatoid arthritis/osteoarthritis.ExposuresCurrent NSAID prescription within the 4 months before 1st March 2020.Main Outcome and MeasureWe used Cox regression to estimate hazard ratios (HRs) for COVID-19 related death in people currently prescribed NSAIDs, compared with those not currently prescribed NSAIDs, adjusting for age, sex, comorbidities and other medications.ResultsIn Study 1, we included 535,519 current NSAID users and 1,924,095 non-users in the general population. The crude HR for current use was 1.25 (95% CI, 1.07–1.46), versus non-use. We observed no evidence of difference in risk of COVID-19 related death associated with current use (HR, 0.95, 95% CI, 0.80–1.13) in the fully adjusted model.In Study 2, we included 1,711,052 people with rheumatoid arthritis/osteoarthritis, of whom 175,631 (10%) were current NSAID users. The crude HR for current use was 0.43 (95% CI, 0.36–0.52), versus non-use. In the fully adjusted model, we observed a lower risk of COVID-19 related death (HR, 0.78, 95% CI, 0.65–0.94) associated with current use of NSAID versus non-use.Conclusion and RelevanceWe found no evidence of a harmful effect of NSAIDs on COVID-19 related deaths. Risks of COVID-19 do not need to influence decisions about therapeutic use of NSAIDs.

Publisher

Cold Spring Harbor Laboratory

Reference52 articles.

1. World Health Organization. Coronavirus disease (COVID-19). Accessed August 5, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019

2. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

3. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

4. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

5. The DataLab. BNF 10.1.1: Non-steroidal anti-inflammatory drugs | Primary Care Prescriptions. OpenPrescribing. Accessed July 13, 2020. https://openprescribing.net/bnf/100101/

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3